Krsnaa Diagnostics Releases Q4 FY26 Earnings Call Transcript
Krsnaa Diagnostics released its Q4 FY26 earnings call transcript. For FY26, revenues were ₹7,728 million and PAT was ₹1,014 million. The company plans ₹5,000 million capex for FY27 and has ₹6,000-7,000 crores revenue visibility over 5-7 years. A dividend of ₹2 per share was recommended. Rajasthan operations are expected to start contributing from Q1 FY27.
The announcement provides detailed financial results, operational updates, and future outlook, including capex plans and revenue visibility. This information is material for investors and analysts assessing the company's performance and prospects.
The announcement is a transcript of an earnings call, which primarily provides factual information about financial results and operational updates. While the results show growth, the transcript also includes discussions about execution challenges and conservative guidance, leading to a neutral sentiment.
Krsnaa Diagnostics Limited has released the transcript of its earnings conference call held on May 26, 2026, to discuss the audited financial results for the quarter and year ended March 31, 2026. The call featured discussions on the company's unique integrated radiology and pathology platform, its Public-Private Partnership (PPP) led model aimed at improving healthcare infrastructure in India, and its strategic expansion plans.
During the call, management highlighted that for FY26, revenues stood at approximately ₹7,728 million, with EBITDA at approximately ₹2,149 million (28% margin). Profit After Tax (PAT) grew significantly to approximately ₹1,014 million for the full year, with Q4 PAT alone reaching approximately ₹417 million, a year-on-year increase of over 101%. The company also noted its extensive operational footprint, including over 190 CT and MRI centers, 147 pathology laboratories, and more than 4,700 patient collection centers across 18 states.
Key strategic points discussed included the company's capital expenditure of nearly ₹5,000 million across Rajasthan, CT/MRI expansions, and retail infrastructure, leading to long-term revenue visibility of ₹6,000 to ₹7,000 crores over the next 5-7 years. The retail diagnostics business contributed approximately 8% to revenues in FY26 and is expected to grow significantly. The company also mentioned a dividend recommendation of ₹2 per share (40% of face value).
Discussions also covered the ramp-up of operations in Rajasthan, expected to contribute revenues from Q1 FY27, with an estimated annual revenue potential of ₹100-150 crores. The company reiterated its commitment to maintaining EBITDA margins around 28-30% and improving working capital efficiency, with a target to reduce Days Sales Outstanding (DSO) to below 120 days in FY27. Management also addressed the progress on radiology projects, including the addition of MRI centers, and provided color on the revenue split between pathology and radiology (approximately 50-50).
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.